Nuvectis Pharma, Inc. NVCT Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $31.63M+70.7% | $18.53M-3.1% | $19.13M-4.3% | $19.99M+248% | ||
| $75K+1.4% | $74K+25.4% | $59K-85.7% | $412K+353% | ||
| $31.71M+70.4% | $18.61M-3.0% | $19.19M-6.0% | $20.41M+250% | ||
| $31.71M+70.4% | $18.61M-3.0% | $19.19M-6.0% | $20.41M+207% | ||
| $6.27M+151% | $2.5M-9.9% | $2.77M-4.8% | $2.91M+175% | ||
| $6.91M+24.3% | $5.56M+46.3% | $3.8M+59.5% | $2.38M+1,577% | ||
| $13.3M+49.5% | $8.89M+27.3% | $6.98M+12.9% | $6.19M+156% | ||
| $13.3M+49.5% | $8.89M+27.3% | $6.98M+12.9% | $6.19M+156% | ||
| $118.1M+42.4% | $82.96M+24.9% | $66.45M+43.8% | $46.2M+2,342% | ||
| -$99.69M-36.1% | -$73.25M-35.0% | -$54.25M-69.6% | -$31.99M-148% | ||
| $18.41M+89.6% | $9.71M-20.4% | $12.2M-14.2% | $14.22M+229% | ||
| $31.71M+70.4% | $18.61M-3.0% | $19.19M-6.0% | $20.41M+207% | ||
| $75K+1.4% | $74K+25.4% | $59K-85.7% | $412K+353% | ||
| $6.91M+24.3% | $5.56M+46.3% | $3.8M+59.5% | $2.38M+1,577% | ||
| $115K-86.3% | $840K+102% | $415K-6.7% | $445K+12.7% | ||
| $115K-86.3% | $840K+102% | $415K-6.7% | $445K+12.7% | ||
| $6.91M+24.3% | $5.56M+46.3% | $3.8M+59.5% | $2.38M+1,577% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Nuvectis Pharma, Inc.'s total assets?
- Nuvectis Pharma, Inc. (NVCT) holds $25.4M in total assets, down 15.8% year over year.
- How much cash does Nuvectis Pharma, Inc. have?
- Nuvectis Pharma, Inc. holds $25.1M in cash and equivalents.
- Can Nuvectis Pharma, Inc. cover its short-term obligations?
- Its current ratio is 2.27 — current assets exceed current liabilities.
- Where does Nuvectis Pharma, Inc.'s balance sheet data come from?
- Every line is extracted from Nuvectis Pharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.